Cell Death and Disease,
Год журнала:
2023,
Номер
14(9)
Опубликована: Сен. 20, 2023
Abstract
Aldehyde
dehydrogenase
3A1
(ALDH3A1)
is
an
NAD
+
-dependent
enzyme
that
closely
related
to
tumor
development.
However,
its
role
in
non-small-cell
lung
cancer
(NSCLC)
has
not
been
elucidated.
This
study
aimed
clarify
the
mechanism
of
ALDH3A1
and
identify
potential
therapeutic
targets
for
NSCLC.
Here,
first
time,
we
found
expression
could
be
induced
by
a
hypoxic
environment
was
highly
expressed
NSCLC
tissue,
especially
some
late-stage
patients,
associated
with
poor
prognosis.
In
mechanistic
terms,
enhances
glycolysis
suppresses
oxidative
phosphorylation
(OXPHOS)
promote
cell
proliferation
activating
HIF-1α/LDHA
pathway
addition,
results
showed
target
β-elemene.
can
downregulated
β-elemene
inhibit
enhance
OXPHOS,
thus
suppressing
vitro
vivo.
conclusion,
hypoxia-induced
energy
metabolic
status
tumors
efficacy
β-elemene,
providing
new
theoretical
basis
better
clinical
applications
Cancer Research,
Год журнала:
2023,
Номер
83(12), С. 1953 - 1967
Опубликована: Апрель 16, 2023
Mutations
in
the
KEAP1-NRF2
(Kelch-like
ECH-associated
protein
1-nuclear
factor-erythroid
2
p45-related
factor
2)
pathway
occur
up
to
a
third
of
non-small
cell
lung
cancer
(NSCLC)
cases
and
often
confer
resistance
therapy
poor
outcomes.
Here,
we
developed
murine
alleles
KEAP1
NRF2
mutations
found
human
NSCLC
comprehensively
interrogated
their
impact
on
tumor
initiation
progression.
Chronic
stabilization
by
Keap1
or
Nrf2
mutation
was
not
sufficient
induce
tumorigenesis,
even
absence
suppressors,
p53
LKB1.
When
combined
with
KrasG12D/+,
constitutive
activation
promoted
early
progression
hyperplasia
low-grade
tumors
but
impaired
advanced-grade
tumors,
which
reversed
deletion.
Finally,
overexpression
mutant
lines
detrimental
proliferation,
viability,
anchorage-independent
colony
formation.
Collectively,
these
results
establish
context-dependence
activity
threshold
for
during
tumorigenic
process.
Cell Reports,
Год журнала:
2024,
Номер
43(4), С. 114104 - 114104
Опубликована: Апрель 1, 2024
Clinical
evidence
has
revealed
that
high-level
activation
of
NRF2
caused
by
somatic
mutations
in
(NFE2L2)
is
frequently
detected
esophageal
squamous
cell
carcinoma
(ESCC),
whereas
KEAP1,
a
negative
regulator
NRF2,
not.
Here,
we
aspire
to
generate
mouse
model
NRF2-activated
ESCC
using
the
cancer-derived